Delving into the Latest Updates on Carotuximab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105

+ [3]

Target

ENG

Mechanism

ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal DiseasesRespiratory Diseases

Active Indication

Hormone receptor positive HER2 negative breast cancerLocally advanced breast cancerEGFR-mutated non-small Cell Lung Cancer

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAdvanced Renal Cell Carcinoma+ [35]

Originator Organization

Roswell Park Comprehensive Cancer Center

Active Organization

TRACON Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corp.

Inactive Organization

Ambrx, Inc.

National Cancer Institute

Santen Pharmaceutical Co., Ltd.

+ [1]

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 319922187H

Source: *****

Sequence Code 319922188L

Source: *****

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Start Date27 Dec 2023

Sponsor / Collaborator-

NCT05401110 / RecruitingPhase 1IIT

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Start Date15 Sep 2023

Sponsor / Collaborator

Enviro Therapeutics, Inc.

NCT03418324 / CompletedPhase 2IIT

A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy

This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.

Start Date05 Mar 2018

Sponsor / Collaborator

Cedars-Sinai Medical Center

100 Clinical Results associated with Carotuximab

Login to view more data

100 Translational Medicine associated with Carotuximab

Login to view more data

100 Patents (Medical) associated with Carotuximab

Login to view more data

82

Literatures (Medical) associated with Carotuximab

01 Apr 2023·Breast cancer research and treatment

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Article

Author: Acosta, Edward P ; Vaklavas, Christos ; Wei, Shi ; Grizzle, William E ; Stringer-Reasor, Erica M ; Forero-Torres, Andres ; Li, Yufeng ; Elkhanany, Ahmed M ; Ryan, Kevin J ; Theuer, Charles P ; Yang, Eddy S

Abstract:

Purpose:

In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer.

Methods:

Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity.

Results:

Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy.

Conclusion:

Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.

Trial registration:

This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.

01 Jan 2023·Molecular therapy : the journal of the American Society of Gene Therapy

Antagonizing CD105 and androgen receptor to target stromal-epithelial interactions for clinical benefit

Article

Author: Zhang, Le ; Posadas, Edwin M ; Kim, Minhyung ; You, Sungyong ; Billet, Sandrine ; Duong, Frank ; Madhav, Anisha ; Placencio-Hickok, Veronica R ; Smith, Bethany N ; Angara, Bryan ; Scher, Kevin ; Bhowmick, Neil A ; Oppenheim, Amy ; Moldawer, Nancy ; Tighiouart, Mourad ; Mishra, Rajeev

Androgen receptor signaling inhibitors (ARSIs) are standard of care for advanced prostate cancer (PCa) patients. Eventual resistance to ARSIs can include the expression of androgen receptor (AR) splice variant, AR-V7, expression as a recognized means of ligand-independent androgen signaling. We demonstrated that interleukin (IL)-6-mediated AR-V7 expression requires bone morphogenic protein (BMP) and CD105 receptor activity in both PCa and associated fibroblasts. Chromatin immunoprecipitation supported CD105-dependent ID1- and E2F-mediated expression of RBM38. Further, RNA immune precipitation demonstrated RBM38 binds the AR-cryptic exon 3 to enable AR-V7 generation. The forced expression of AR-V7 by primary prostatic fibroblasts diminished PCa sensitivity to ARSI. Conversely, downregulation of AR-V7 expression in cancer epithelia and associated fibroblasts was achieved by a CD105-neutralizing antibody, carotuximab. These compelling pre-clinical findings initiated an interventional study in PCa patients developing ARSI resistance. The combination of carotuximab and ARSI (i.e., enzalutamide or abiraterone) provided disease stabilization in four of nine assessable ARSI-refractory patients. Circulating tumor cell evaluation showed AR-V7 downregulation in the responsive subjects on combination treatment and revealed a three-gene panel that was predictive of response. The systemic antagonism of BMP/CD105 signaling can support ARSI re-sensitization in pre-clinical models and subjects that have otherwise developed resistance due to AR-V7 expression.

01 Jan 2023·Frontiers in medicine

Endoglin and squamous cell carcinomas.

Article

Author: Boonstra, Jurjen J ; Harryvan, Tom J ; Hakuno, Sarah K ; Janson, Stefanus G T ; Dinjens, Winand N M ; de Jonge-Muller, Eveline ; de Graaf, Manon ; Hawinkels, Lukas J A C ; Slingerland, Marije ; Trietsch, Marjolijn D ; Crobach, Stijn

Despite the fact that the role of endoglin on endothelial cells has been extensively described, its expression and biological role on (epithelial) cancer cells is still debatable. Especially its function on squamous cell carcinoma (SCC) cells is largely unknown. Therefore, we investigated SCC endoglin expression and function in three types of SCCs; head and neck (HNSCC), esophageal (ESCC) and vulvar (VSCC) cancers. Endoglin expression was evaluated in tumor specimens and 14 patient-derived cell lines. Next to being expressed on angiogenic endothelial cells, endoglin is selectively expressed by individual SCC cells in tumor nests. Patient derived HNSCC, ESCC and VSCC cell lines express varying levels of endoglin with high interpatient variation. To assess the function of endoglin in signaling of TGF-β ligands, endoglin was overexpressed or knocked out or the signaling was blocked using TRC105, an endoglin neutralizing antibody. The endoglin ligand BMP-9 induced strong phosphorylation of SMAD1 independent of expression of the type-I receptor ALK1. Interestingly, we observed that endoglin overexpression leads to strongly increased soluble endoglin levels, which in turn decreases BMP-9 signaling. On the functional level, endoglin, both in a ligand dependent and independent manner, did not influence proliferation or migration of the SCC cells. In conclusion, these data show endoglin expression on individual cells in the tumor nests in SCCs and a role for (soluble) endoglin in paracrine signaling, without directly affecting proliferation or migration in an autocrine manner.

2

News (Medical) associated with Carotuximab

02 Nov 2022

·www.sciencedaily.com

Developing therapies for treatment-resistant prostate cancer

In a recent trial, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging Investigators from Cedars-Sinai Cancer have identified an investigational therapeutic approach that could be effective against treatment-resistant prostate cancer. Results of their Phase II clinical trial, published in the peer-reviewed journal Molecular Therapy, have led to a larger, multicenter trial that will soon be underway. Cancer of the prostate, a small gland just below the bladder, is the second-leading cause of cancer-related death in men. Many prostate tumors are not aggressive and may require no or minimal treatment. Aggressive tumors are initially treated with surgery or radiation therapy. In about one-third of patients, the cancer comes back after initial treatment, said Neil Bhowmick, PhD, research scientist at Cedars-Sinai Cancer, professor of Medicine and Biomedical Sciences and senior author of the study. Those patients are usually treated with medications that suppress the actions of testosterone and other androgens -- male hormones that help prostate tumors grow. "Patients do really well until the tumor figures a way around the androgen-suppressing therapy," Bhowmick said. "One way that it can do this is to cause cells to make only part of the protein that the drug binds to, rendering the drug useless. The partial proteins are called splice variants." Through research with human cells and laboratory mice, study first author Bethany Smith, PhD, a project scientist in the Bhowmick Lab, figured out that the cancer cells were signaling to the surrounding supportive cells through a protein called CD105 to make these slice variant proteins. Investigators then conducted a trial in human patients to test a drug that they hoped would keep those partial proteins from forming by inhibiting CD105. In the trial, nine patients whose tumors were resistant to androgen-blocking therapy continued that therapy but were also given a CD105 inhibitor called carotuximab. Forty percent of those patients experienced progression-free survival, based on radiographic imaging. "Every single one of the patients in our trial was totally resistant to at least one androgen suppressor, and the normal course of action would be to simply try a different one or chemotherapy, which research has shown generally doesn't stop tumor growth for more than about three months," Bhowmick said. "Carotuximab prevented the cancer's workaround and made the tumor sensitive to androgen-suppressing therapy." Importantly, Bhowmick said, carotuximab also appears to prevent androgen receptor splice variants in the supporting cells surrounding tumors, further sensitizing the tumor to the androgen suppressor. "We found that this therapy may be able to, especially in early cancers, resensitize select patients to androgen suppression. This could allow patients to avoid or delay more toxic interventions such as cytotoxic chemotherapy," said Edwin Posadas, MD, co-director of the Experimental Therapeutics Program, medical director of the Urologic Oncology Program/Center for Uro-Oncology Research Excellence (CURE), associate professor of Medicine at Cedars-Sinai and a co-author of the study. "We also hope to find ways of predicting which patients are most likely to benefit from this approach by testing blood and tissue samples using next-generation technologies housed at Cedars-Sinai Cancer." Study co-author Sungyong You, PhD, director of the Urologic Oncology Bioinformatics Group, pinpointed three biomarkers that could help indicate which patients will respond to this investigational therapy, and the team will validate those markers in a new clinical trial. This will allow future studies to target patients most likely to be helped by this intervention, Bhowmick said. Funding: The study was supported by Department of Defense grant number W81XWH-17-1-0154 and Veterans Administration grant number I01BX001040.

Small molecular drugRadiation Therapy

19 Jan 2018

·www.globenewswire.com

TRACON Pharmaceuticals Announces Positive Data from Ongoing Phase 1b/2 Trial of TRC105 in Hepatocellular Carcinoma Patients

Two Partial Responses (25%) by RECIST and Three > 50% Reductions of Alpha Fetoprotein in Eight Evaluable Patients (38%) Treated to Date with Combination of TRC105 and Nexavar® Data Presented at ASCO 2018 Gastrointestinal Cancers Symposium SAN DIEGO, Jan. 19, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, today announced that positive initial clinical data from its ongoing Phase 1b/2 study of TRC105 and Nexavar® (sorafenib) in patients with advanced hepatocellular carcinoma (HCC) were presented in a poster presentation at the 2018 ASCO Gastrointestinal Cancers Symposium in San Francisco, California. Initial data from the ongoing open-label, non-randomized study were presented by Dr. Kanwal Raghav from the University of Texas MD Anderson Cancer Center: Partial responses by RECIST 1.1 occurred in 2 of 8 (25%) evaluable patients and a reduction of 50% or greater in alpha fetoprotein (AFP) concentration occurred in 3 of 8 (38%) evaluable patients. Reduction in AFP, a tumor marker expressed in patients with HCC, in early treatment may help identify a favorable response to treatment and was observed in both cases of partial response. Hybrid dosing consisting of four weekly doses of TRC105 at 10 mg/kg followed by every other week dosing at 15 mg/kg thereafter was tolerable when given with the standard Nexavar dose of 400 mg twice daily. Adverse events typical of each drug did not increase in frequency or severity when the drugs were administered concurrently. The trial is ongoing, with the completion of the enrollment of approximately 33 patients expected by the end of 2018. “We continue to be encouraged with the safety and activity of TRC105 in combination with Nexavar in patients with HCC, a tumor type with limited treatment options,” said Charles Theuer, M.D., Ph.D., President and CEO of TRACON. “Importantly, the initial data from the current trial are consistent with the 33% partial response rate by RECIST 1.1 reported in the completed Phase 1/2 study published by the National Cancer Institute in 2017. We expect to complete enrollment of the current multicenter study by the end of 2018, and will discuss a potential registration-enabling study of the combination of TRC105 and Nexavar in HCC with regulatory authorities shortly thereafter.” The poster is available on TRACON’s website at: www.traconpharma.com/publications.php About Carotuximab ( TRC105 ) TRC105 is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in a pivotal Phase 3 trial in angiosarcoma and multiple Phase 2 clinical trials, in combination with VEGF inhibitors. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the U.S. and EU. The ophthalmic formulation of TRC105, DE-122, is currently in a randomized Phase 2 trial for patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php . About TRACON TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com . Forward-Looking Statements This press release contains forward-looking statements, including statements regarding TRACON’s plans and timing with respect to on-going clinical trials, and other development plans and potential benefits of TRACON’s product candidates. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include, but are not limited to, the fact that initial clinical trial results or results from prior studies may not be consistent with subsequent results, TRACON’s and others’ ability to identify and enroll patients in on-going and planned clinical trials, potential delays in completing on-going clinical trials, whether TRACON’s product candidates will be shown to be safe and effective in subsequent studies, and TRACON’s and others’ ability and willingness to fund additional clinical development of TRACON’s product candidates. For a further description of these and other risks facing TRACON, please see the risk factors described in TRACON’s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and TRACON undertakes no obligation to update or revise these statements, except as may be required by law. Company Contact : Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 clogan@traconpharma.com Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com

CollaborateAntibodySmall molecular drugASCO

100 Deals associated with Carotuximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11260	-	-	DB06322

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemangiosarcoma	Phase 3	US	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	AT	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	FR	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	DE	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	IT	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	PL	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	ES	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	GB	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Metastatic castration-resistant prostate cancer	Phase 2	US	Cedars-Sinai Medical Center	05 Mar 2018
Wet age-related macular degeneration	Phase 2	US	Santen Pharmaceutical Co., Ltd.	05 Jul 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02520063 (CTgov)	Phase 1/2	Locally advanced breast cancer \| Hormone receptor positive HER2 negative breast cancer	15	Letrozole+everolimus+TRC105 (Phase I Cohort 1)	hityljcqad(odmykzttav) = yznqxbdpyu xfpaylqjec (nzffxooicc, achrerhtvo - tiqiwqxmdh) View more	-	21 Aug 2023
				Letrozole+everolimus+TRC105 (Phase I Cohort 2)	hityljcqad(odmykzttav) = cyapmpwief xfpaylqjec (nzffxooicc, oziwaiomuc - bbbkgmwoxi) View more
NCT02979899 (TAPPAS, Pubmed) Manual	Phase 3	Hemangiosarcoma	114	TRC105+Pazopanib	waybynmbva(dmglzhcjbh) = ebbzttgdzl cbyymfqweb (qvcjhiijnp, 2.8 ~ 8.3)	Positive	31 Mar 2022
				Pazopanib	waybynmbva(dmglzhcjbh) = oghbcpeexg cbyymfqweb (qvcjhiijnp, 2.9 ~ NR)
NCT03211234 (CTgov)	Phase 2	Wet age-related macular degeneration	76	Lucentis (Sham)	vtnfpdjvno(wkyrmdtmgo) = xhfkwtwolq veeumgofvz (fvefitaikn, cgegnkhedt - kpuyrqdbvm) View more	-	13 Jul 2021
				DE-122+Lucentis (2.0 mg DE-122)	vtnfpdjvno(wkyrmdtmgo) = wpfeqdpcte veeumgofvz (fvefitaikn, ugovsgpdad - xvvfvjlszd) View more
NCT03418324 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic castration-resistant prostate cancer	11	Abiraterone+TRC105 (Arm A: TRC105 + Abiraterone)	zkkhxflonj(djndiqatzz) = hirrsshrsa cobkscqkfn (vaclltwirr, yaoxbtvntb - nxyztqlrgq) View more	-	30 Dec 2020
				Enzalutamide+TRC105 (Arm E: TRC105 + Enzalutamide)	zkkhxflonj(djndiqatzz) = bcebscuoga cobkscqkfn (vaclltwirr, gzxozogurd - wwrkoulvap) View more
NCT01806064 (TRAXAR, CTgov)	Phase 1/2	Metastatic Renal Cell Carcinoma	173	Axitinib+TRC105 (P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	fbxzkitgad(hvyjcdnjkj) = pbwpknbsrd jsalvtabiv (gtbuuazthi, hfawcvhuyr - ngojclwrto) View more	-	19 Oct 2020
				Axitinib+TRC105 (P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	fbxzkitgad(hvyjcdnjkj) = pbebgnasew jsalvtabiv (gtbuuazthi, eywdgruous - pqgzigannt) View more
NCT02560779 (CTgov)	Phase 1/2	Hepatocellular Carcinoma	27	Carotuximab+Sorafenib (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)	ltvwbjqpxh(xkbjvpnqbx) = edostqujxl geynotggln (qxesrgexob, bindxuhszy - tibjmomgvb) View more	-	17 Jul 2020
				Carotuximab+Sorafenib (Carotuximab (10 mg/kg Weekly) Plus Sorafenib)	ltvwbjqpxh(xkbjvpnqbx) = chcmuxvwna geynotggln (qxesrgexob, okzskhewca - cmnepsttqk) View more
NCT03181308 (CTgov)	Phase 1	metastatic non-small cell lung cancer	11	Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab)	csqvwktlmr(jtpcyxgtqv) = bfjajhzsos fsuhdxtley (pneqwkpulk, nuyiktrjeo - yhrdbcfypf) View more	-	24 Jun 2020
				Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab)	csqvwktlmr(jtpcyxgtqv) = otjseqrmnk fsuhdxtley (pneqwkpulk, mifwwijobk - wlpecfmzvt) View more
NCT01975519 (CTgov)	Phase 1/2	Sarcoma	111	TRC105+Pazopanib (TRC105 Plus Pazopanib)	pmultaqjrv(altegovoha) = hnliojkvjg dhmtkypfxv (djvmabbhmw, ygpcousyfr - nzabxplmyb) View more	-	12 May 2020
				TRC105+Pazopanib (8 mg/kg TRC105 + Pazopanib)	aqbkavaspd(iytxvbrnwz) = bmnoptubtp gkoymujlwf (qzxttlnnrv, uiyloaonik - jdrychlqxa) View more
NCT02979899 (TAPPAS, CTgov)	Phase 3	Hemangiosarcoma	128	Votrient	opfrhwqsmg(qibqnyxwzt) = fqnpcqbksd aucypzuxcq (twhwfonfsm, rqdrdhqpnq - hehmdcyfse) View more	-	12 May 2020
NCT02555306 (CTgov)	Phase 1/2	Age Related Macular Degeneration	12	DE-122 (0.5 mg of DE-122)	jabfpifcrd(pvyjdzltfr) = sbegaglobo rrylrkdnbz (dpmzyaqozh, cvolbrotxa - uqsldoegiu) View more	-	14 Jan 2020
				DE-122 (1.0 mg of DE-122)	jabfpifcrd(pvyjdzltfr) = doplfqcxdp rrylrkdnbz (dpmzyaqozh, nndhnzdafv - mhpzjeocrp) View more